Obesity evidence dossier
Elecoglipron
A late-stage oral GLP-1RA with peer-reviewed Phase 2 obesity efficacy; pivotal Phase 3 weight-management results are pending.
Total weight loss
10.5%
VISTA · 75 mg daily, weekly titration · week 26 · Analysis not fully specified
Placebo-adjusted
9.9%
Difference from placebo in the same study when reported.
Study context
Once-daily oral small-molecule GLP-1 receptor agonist./Adults with obesity or overweight, without diabetes/310 participants across the study/26-week endpoint
Baseline: See the source for enrollment criteria
Ranked result & calculation
VISTA · 75 mg daily, weekly titration · 26 weeks
Adults with obesity or overweight, without diabetes. 310 participants across the study (not this dose arm alone).
Analysis not fully specified. The source does not establish a treatment-policy analysis; interpret this score provisionally. Estimated primary-endpoint means; treatment-policy status is not specified in the indexed abstract.
- Average weight loss
- 10.5%
- Placebo group
- 0.6% loss
- Beyond placebo
- 9.9 percentage points (arm subtraction)
- Stopped due to adverse events
- Not verified for this result
Primary result at week 26 in a 36-week study.
Score: 70% × 42.2 total-loss points + 30% × 49.5 beyond-placebo points = 44/100, rounded. Conversion scales
VISTA, Lancet ↗Phase 2 · Journal article · Reviewed 2026-09-21
Evidence
Benchmark read
VISTA: Analysis not fully specified. Estimated primary-endpoint means; treatment-policy status is not specified in the indexed abstract. Primary result at week 26 in a 36-week study.
Safety
Side effects and cautions
Discontinuation read
Adverse-event discontinuation has not been verified for this result.
Common side effects
Phase 2 reporting characterized tolerability as consistent with the GLP-1RA class, with gastrointestinal adverse events the principal practical concern.
Main cautions
Investigational; efficacy estimates derive from an efficacy estimand and Phase 2 follow-up, so they should not be treated as Phase 3 effectiveness results.
Upcoming catalyst
What to watch next
EMBOLD Phase 3 72-week weight-management outcomes.
Linked clinical trials
Trials in the saddl3 obesity snapshot
Non-diabetic obesity studies are prioritized; diabetes and healthy-volunteer studies remain visible and labeled.
NCT06579092
Phase 2
Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related Comorbidity
AstraZeneca
Non-diabetic obesity
Dec 18, 2025
NCT06988553
Phase 1
A Phase Ib Study of AZD5004 in Chinese Participants With Overweight/Obesity With or Without Type 2 Diabetes Mellitus
Eccogene
Type 2 diabetes / obesity
Dec 23, 2025